US Patent 8,071,648: Claim Scope, Expiration, Orange Book Position, and Nepafenac Patent Landscape

US Patent 8,071,648 is a narrow formulation patent directed to a 0.1% nepafenac ophthalmic composition containing carbomer, tyloxapol, sodium chloride, mannitol, benzalkonium chloride, edetate disodium, a pH-adjusting agent, and purified water. Claim 1 requires the listed ingredients, the stated concentrations, and a pH of 7.3 to 7.7. It does not broadly claim nepafenac, the treatment of ocular inflammation, or every nepafenac ophthalmic formulation.

The claim has high product-identification value but limited formulation breadth. A competing product that changes one required ingredient, materially changes a concentration, uses a different vehicle, or falls outside the claimed pH range may avoid literal infringement. The principal commercial relevance is therefore to generic versions that closely copy the reference formulation.

What does US Patent 8,071,648 claim?

Claim 1 is a product claim covering a topically administrable ophthalmic composition with nine required elements:

Claim element	Required limitation
Nepafenac	0.1% w/v
Carbomer	0.5% w/v
Tyloxapol	0.01% w/v
Sodium chloride	0.4% w/v
Mannitol	2.4% w/v
pH-adjusting agent	Amount sufficient for pH 7.3-7.7
Benzalkonium chloride	0.005% w/v
Edetate disodium	0.01% w/v
Water	Purified water
Dosage form	Topically administrable ophthalmic composition

The claim is drafted with the transition “consisting of.” That language generally closes the claimed composition to additional components that materially alter the claimed combination. It is narrower than “comprising,” which ordinarily permits additional ingredients.

The patent is US Patent No. 8,071,648 B2, assigned to Alcon Research, Ltd. The patent was issued on December 6, 2011. The patent is associated with the development and protection of a nepafenac ophthalmic formulation corresponding closely to the formulation used for Nevanac, a 0.1% nepafenac ophthalmic suspension marketed by Alcon.[1][2]

How narrow is the scope of claim 1?

Claim 1 is narrow in composition but potentially meaningful in practice because it identifies a commercially recognizable formulation.

A product would generally need to satisfy each of the following conditions for literal infringement:

It is suitable for topical ophthalmic administration.
It contains nepafenac at 0.1% w/v.
It contains carbomer at 0.5% w/v.
It includes tyloxapol, sodium chloride, mannitol, benzalkonium chloride, edetate disodium, and purified water at the stated levels.
Its pH is between 7.3 and 7.7.
It does not materially add ingredients excluded by “consisting of.”

The claim does not identify a particular carbomer grade. A formulation using carbomer 974P, carbomer 934P, or another pharmaceutically acceptable carbomer could fall within the claim if the selected material meets the claim construction adopted by a court. The absence of a grade limitation increases the claim’s potential reach within the carbomer class.

The claim also does not specify the identity of the pH-adjusting agent. Hydrochloric acid, sodium hydroxide, or another suitable agent could satisfy that limitation, provided it is present in an amount sufficient to produce the required pH.

Why the exact concentrations matter

The concentrations are expressed in % w/v, meaning grams per 100 milliliters of finished composition. The claim therefore requires:

0.1 grams of nepafenac per 100 mL;
0.5 grams of carbomer per 100 mL;
0.01 grams of tyloxapol per 100 mL;
0.4 grams of sodium chloride per 100 mL;
2.4 grams of mannitol per 100 mL;
0.005 grams of benzalkonium chloride per 100 mL; and
0.01 grams of edetate disodium per 100 mL.

Minor manufacturing variation does not automatically defeat infringement. Courts may assess whether a product is within a reasonable analytical range or whether a limitation is inherently present. A materially different declared concentration, however, creates a stronger non-infringement position.

What formulation is associated with US 8,071,648?

The claimed formulation is associated with the 0.1% nepafenac ophthalmic suspension sold as Nevanac. FDA labeling identifies Nevanac as a sterile topical ophthalmic suspension containing nepafenac 0.1% and lists inactive ingredients including carbomer, glycerin or mannitol-related tonicity agents, sodium chloride, tyloxapol, benzalkonium chloride, edetate disodium, and purified water, with pH adjustment.[2]

Nevanac is indicated for the treatment of pain and inflammation associated with cataract surgery. Nepafenac is a prodrug converted to amfenac, a cyclooxygenase inhibitor. The commercial formulation uses a suspension and requires shaking before administration.[2]

The presence of the same or substantially similar excipients in a generic product is not by itself sufficient to establish infringement. The relevant question is whether the approved formulation and manufacturing specifications meet every limitation of the asserted claim.

When does US Patent 8,071,648 expire?

The patent was issued on December 6, 2011. Its nominal term is generally measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and other statutory calculations.[1][3]

Public patent records associate the patent with a 2007 priority period. On that basis, the unadjusted patent term would generally fall in 2027. The precise enforceable expiration date must be taken from the USPTO patent-term calculation, including any patent-term adjustment shown in the patent record.

Event	Date or period
Patent issued	December 6, 2011
Priority period identified in public patent records	2007
Nominal 20-year term	Generally 2027
Patent-term adjustment	Must be included in the USPTO calculation
Patent status for commercial analysis	Verify against current USPTO maintenance and term records

The patent’s expiration date is distinct from FDA regulatory exclusivity. Patent expiry does not determine whether an ANDA may be approved, and FDA exclusivity does not necessarily extend the patent term.

What is the Orange Book status of US 8,071,648?

The Orange Book status of a patent depends on whether the patent is listed against the relevant approved NDA and whether the listing remains active for the relevant product and indication.[4]

Nevanac was approved under NDA 21-252. The existence of US 8,071,648 does not, by itself, establish that the patent is currently listed in the Orange Book. A definitive listing analysis requires the current Orange Book patent-and-exclusivity data for NDA 21-252 and any corresponding listing history.

The commercial distinction is important:

An Orange Book-listed formulation patent can support a Paragraph IV notice and patent litigation.
A patent that is not listed may still be enforceable against an infringing commercial product.
An unlisted patent generally does not create the same ANDA approval delay available under the Hatch-Waxman listing framework.
An ANDA applicant may certify to a listed patent under Paragraph III, Paragraph IV, or another applicable certification category depending on the patent and regulatory record.[5]

A formulation patent is especially relevant to Paragraph IV analysis when the generic applicant’s proposed label and composition reproduce the reference product.

How does claim 1 affect Paragraph IV challenges?

A generic applicant seeking approval of 0.1% nepafenac ophthalmic suspension could face a Paragraph IV issue if US 8,071,648 is listed for the reference product and the applicant believes the patent is invalid, unenforceable, or not infringed.

The principal Paragraph IV positions would be:

Challenge theory	Potential argument
Non-infringement	One or more required ingredients, concentrations, or pH limitations are absent
“Consisting of” limitation	The generic contains an additional ingredient outside the claimed closed composition
Invalidity for anticipation	A single prior-art reference discloses the full claimed combination
Invalidity for obviousness	The claimed excipient combination and concentrations would have been obvious
Indefiniteness	A limitation, such as “topically administrable,” lacks sufficient boundaries
Written description or enablement	The specification does not adequately support the full scope of the claim
Enforceability	Inequitable conduct or other conduct-based defense, if supported by evidence

The exact-combination requirement makes anticipation difficult unless a prior-art reference discloses all listed components and concentrations. Obviousness is more plausible because ophthalmic formulation scientists routinely select tonicity agents, preservatives, surfactants, chelating agents, viscosity modifiers, and pH adjusters. The patent holder’s response would likely focus on the claimed combination, formulation stability, nepafenac suspension performance, ocular tolerability, and any unexpected properties shown in the specification.

What design-around options exist for generic manufacturers?

Potential design-around routes include:

Replacing carbomer with another viscosity-enhancing polymer.
Using a different concentration of carbomer.
Omitting tyloxapol or substituting another surfactant.
Using a different tonicity system instead of sodium chloride and mannitol.
Changing the preservative or using a preservative-free multidose delivery system.
Selecting a pH below 7.3 or above 7.7.
Using a different chelating agent or omitting edetate disodium.
Developing a different suspension vehicle or particle-size distribution.

A design-around must be evaluated against both literal infringement and the doctrine of equivalents. A small change made solely to evade a numerical limitation may invite an equivalents argument, particularly if the substitute performs substantially the same function in substantially the same way. A different excipient system, preservative strategy, or delivery device presents a stronger technical distinction.

How strong is the patent estate for nepafenac?

US 8,071,648 is best characterized as a formulation-specific asset, not a broad nepafenac platform patent.

Patent category	Relevance to generic entry
Active ingredient patent	Protects nepafenac or its chemical substance; generally the broadest category
Basic ophthalmic composition patent	May cover broad nepafenac formulations
Specific formulation patent	Targets exact excipients, concentrations, pH, or physical properties
Method-of-use patent	Covers treatment of a defined ocular condition or surgical indication
Manufacturing patent	May cover particle size, milling, suspension processing, sterilization, or filling
Device or packaging patent	May protect delivery-system features

The supplied claim does not claim a method of treating inflammation, cataract-surgery pain, or another disease. It also does not expressly claim a manufacturing process, particle-size distribution, polymorph, or container-closure system. Its value depends on whether a proposed generic reproduces the claimed formulation.

What patent litigation and settlement risks apply?

No litigation conclusion should be drawn from the patent number alone. Relevant records include district-court complaints, ANDA case dockets, Federal Circuit opinions, Orange Book certifications, and settlement terms.

For a listed formulation patent, the principal timing risks are:

a 30-month stay triggered by a timely Paragraph IV notice and suit;
settlement terms restricting launch or permitting an authorized generic;
an agreed launch date before patent expiration;
covenants not to sue covering a redesigned formulation;
separate litigation over patents not listed in the Orange Book.

A settlement involving an earlier generic launch does not necessarily establish that the patent is weak. It may reflect the value of an agreed entry date, commercial launch economics, or an authorized-generic arrangement.

What generic launch scenarios exist?

Early launch after Paragraph IV resolution

A generic may launch before the nominal patent expiration if the patent is found invalid or not infringed, if the patent is delisted or otherwise unavailable as an approval barrier, or if the parties settle on an earlier entry date.

Launch at patent expiration

If the generic reproduces the patented formulation and no earlier entry right exists, launch risk centers on the calculated patent expiration date, any terminal disclaimer, and enforceable pediatric or regulatory extensions.

Non-infringing formulation launch

A generic may seek approval with a formulation that differs from claim 1. The product must still satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, quality, sterility, stability, and labeling.[6]

Authorized generic

The brand holder or its licensee may commercialize an authorized generic under the NDA framework. That can reduce the economic impact of independent generic entry even when patent barriers have expired.

What is the geographic coverage of US 8,071,648?

The patent provides rights only in the United States. Foreign counterparts, if any, must be analyzed separately by country. Relevant differences include:

national-phase claim scope;
patent-term calculations;
supplementary protection certificates;
local patent-linkage rules;
Orange Book equivalents;
local formulation and manufacturing claims; and
litigation or opposition history.

A US non-infringement or invalidity result does not determine the outcome in Canada, Europe, Japan, China, or other markets.

Key Takeaways

US 8,071,648 is a narrow formulation patent for a specific 0.1% nepafenac ophthalmic composition.
Claim 1 requires all listed ingredients, the stated concentrations, purified water, and a pH of 7.3 to 7.7.
The “consisting of” transition materially limits the claim against formulations with additional ingredients.
The claim is closely associated with the Nevanac formulation but does not broadly claim nepafenac or every ophthalmic use.
The patent’s nominal term generally points to 2027, subject to USPTO patent-term adjustment and other term calculations.
A generic developer has credible design-around routes based on excipient selection, concentration, preservative strategy, and pH.
Orange Book listing must be confirmed from the current NDA 21-252 listing data; the patent number alone does not establish listing status.
The main commercial risk is highest for a generic that substantially copies the branded formulation rather than for a materially redesigned product.

FAQs

Does changing only the nepafenac concentration avoid US 8,071,648?

It may avoid literal infringement of claim 1 because 0.1% nepafenac is an express limitation. The change would still require FDA support and would face potential doctrine-of-equivalents analysis.

Does claim 1 cover a nepafenac solution?

Not necessarily. Claim 1 does not expressly use “suspension,” but the complete formulation and physical characteristics must satisfy the claim. A solution would need to meet every compositional limitation and would also require appropriate FDA approval.

Does using a different preservative avoid the patent?

Potentially. Benzalkonium chloride at 0.005% is expressly required. A different preservative may avoid literal infringement, although the overall product would remain subject to equivalents and other patent claims.

Can a generic launch before patent expiration with a non-infringing formulation?

Yes, subject to FDA approval, regulatory exclusivity, applicable Orange Book certifications, and the absence of other enforceable patents or injunctions.

Does US 8,071,648 protect nepafenac manufacturing methods?

Claim 1, as provided, is a composition claim. It does not expressly claim synthesis, milling, particle-size control, sterilization, filling, or another manufacturing method.

References

United States Patent No. 8,071,648 B2. (2011). Ophthalmic compositions containing nepafenac. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (2023). Nevanac (nepafenac ophthalmic suspension) prescribing information.
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
21 U.S.C. § 355(j).
U.S. Food and Drug Administration. (2009). Abbreviated new drug application approvals.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	052252	⤷ Start Trial
Austria	E476200	⤷ Start Trial
Australia	2005311738	⤷ Start Trial
Brazil	PI0518904	⤷ Start Trial
Canada	2586807	⤷ Start Trial
China	101068573	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,071,648

Summary for Patent: 8,071,648